Rutinib Cream 15gm

Uses of Rutinib Cream

• Vitiligo

Indications of Rutinib Cream

Ruxolitinib is a Janus kinase (JAK) inhibitor indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Side Effects of Rutinib Cream

Common side effects of Ruxolitinib cream include Nasopharyngitis (3%), Bronchitis (1%), Ear infection (1%), Eosinophil count increased (1%), Urticaria (1%), Diarrhea (1%), Folliculitis (1%), Tonsillitis (1%), Rhinorrhea (1%).

Pharmacology

Ruxolitinib inhibits Janus kinase (JAK) pathways, which are involved in transmitting signals from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function, including inflammation associated with atopic dermatitis. By modulating the JAK signaling pathway, Ruxolitinib prevents the phosphorylation and activation of signal transducers and activators of transcription (STATs), thereby reducing inflammation.

• Absorption: Peak plasma concentration: 449 nM (adults); 110 nM (adolescents). AUC: 3,215 h.nM (adults); 801 h.nM (adolescents).
• Distribution: Ruxolitinib is approximately 97% protein-bound.
• Metabolism: Primarily metabolized by CYP3A4 and to a lesser extent by CYP2C9 in vitro. Half-life: 116 hours.
• Excretion: Excreted mainly via urine (74%) and feces (22%); less than 1% excreted as unchanged drug.

Dosage & Administration of Rutinib Cream

• For atopic dermatitis: Apply a thin layer of Ruxolitinib cream twice daily to affected areas of up to 20% body surface area. Discontinue use when signs and symptoms (e.g., itch, rash, redness) resolve.
• For nonsegmental vitiligo: Apply a thin layer of Ruxolitinib cream twice daily to affected areas of up to 10% body surface area.

Interactions:

• Ruxolitinib is a substrate of CYP3A4. Strong CYP3A4 inhibitors should be avoided as they may increase systemic exposure to Ruxolitinib and lead to adverse reactions.

Contraindications:

Ruxolitinib is contraindicated in patients with known hypersensitivity to the drug or any of its components.

Use in Pregnancy and Lactation:

There is no available data on the use of Ruxolitinib in pregnancy and lactation. Therefore, its use should be carefully considered and only used if the potential benefits outweigh the potential risks, as determined by a healthcare professional.

Precautions & Warnings:

• Serious infections, viral reactivation, and the impact on chronic viral hepatitis reactivation should be considered before prescribing Ruxolitinib for inflammatory conditions.
• Rutinib Cream is for use on the skin only. Do not use Rutinib Cream in your eyes, mouth, or vagina.

Storage Conditions:

Store below 30°C away from sunlight and keep out of reach of children.